Back to All

Culminatum Innovation and Diaceutics Collaborate to Provide Expert Training to Leading Finnish Researchers on Commercializing Biomarkers for Personalized Medicine

1 January, 2013

Culminatum Innovation and Diaceutics have announced a collaboration aimed at advancing precision medicine. Through this partnership, both companies will leverage their expertise to enhance diagnostic testing strategies and improve patient outcomes.

The collaboration will focus on integrating Culminatum Innovation's innovative technologies with Diaceutics' deep understanding of the diagnostic landscape. By combining their strengths, the two companies aim to streamline the diagnostic process, ensuring patients receive timely and accurate testing for personalized treatment decisions.

This collaboration represents a significant step forward in the field of precision medicine, promising to drive innovation and improve access to advanced diagnostic solutions. Stay tuned for further developments as Culminatum Innovation and Diaceutics work together to shape the future of precision medicine.

Click here to view the full article

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.

Public Relations & Investor Relations advisers

Alma PR
71-73 Carter Lane

Tel: +44 (0)20 3405 0205 or [email protected]

Caroline Forde
Robyn Fisher
Kieran Breheny